Prime Medicine, Inc. (PRME)
Develops gene-editing treatments for inherited diseases like cystic fibrosis and liver disorders.
$3.09+0.03%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago-23.5%
The outlook
Prime Medicine is trading near its 52-week lows, well below its short- and long-term moving averages. Analysts lean bullish with an average price target roughly 130% above the current price, though the stock's recent trend remains weak. The disconnect between bullish coverage and depressed price positioning suggests investors remain cautious on near-term momentum.
What’s behind the score
Analyst consensusBuy — 1.5 avg of 10 analysts
Price trendBelow its 50- & 200-day averages
52-week range10% of the way from its 52-week low to high
Price targetAvg target +130% vs current price
Analyst price target
~12-month · 10 analysts$7.12average target+130.3% vs now
Now $3.09
Low $4.25High $11.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$558.1M
52-wk high
$6.94
52-wk low
$2.67
50-day avg
$3.27
200-day avg
$3.78
Trailing P/E
—